Domenico Albano1, Rexhep Durmo2, Francesco Bertagna3, Raffaele Giubbini3. 1. Nuclear Medicine, Spedali Civili Brescia, Brescia, Italy. doalba87@libero.it. 2. Nuclear Medicine, Spedali Civili Brescia, Brescia, Italy. 3. Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.
Abstract
PURPOSE: Thyroid incidental uptake is defined as a thyroid uptake incidentally detected by imaging examinations performed for non-thyroid disease. The aim of this study was to establish the prevalence and the pathological nature of focal thyroid incidental uptake (FTIU) among patients studied with 18F-choline-PET/CT. MATERIALS AND METHODS: We retrospectively evaluated 368 patients who performed 18F-choline-PET/CT between June 2016 and August 2018. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value (SUVmax) and the mean SUV (SUVmean) of the thyroid gland and of the FTIU; every focal thyroid uptake deviating from physiological distribution and background was considered FTIU. Final diagnosis of FTIU was obtained by cytological or histological examination after surgery. RESULTS: The average SUVmax and SUVmean of thyroid gland in population were 3 and 1.8. Among 368 patients, FTIU was identified in nine cases (2.4%) and eight underwent further investigations to determine the nature. Two FTIU were classified as malignant (thyroid carcinoma), whereas five were benign (three nodular hyperplasia, one follicular adenoma, one Hurtle cell adenoma) and one indeterminate at cytological examination. In malignant lesions, average SUVmax was 9.6 and 4.5, respectively, while average SUVmean was 5.3 and 2.9, respectively. Average SUVmax and SUVmean of benign lesions were 4.9 and 3.2 and of the indeterminate lesion 5 and 3, respectively. CONCLUSIONS: 18F-choline-PET/CT FTIU may be a relevant diagnostic reality, which requires further investigations and affects management, especially considering that, despite being mainly benign, also malignancy is possible.
PURPOSE: Thyroid incidental uptake is defined as a thyroid uptake incidentally detected by imaging examinations performed for non-thyroid disease. The aim of this study was to establish the prevalence and the pathological nature of focal thyroid incidental uptake (FTIU) among patients studied with 18F-choline-PET/CT. MATERIALS AND METHODS: We retrospectively evaluated 368 patients who performed 18F-choline-PET/CT between June 2016 and August 2018. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value (SUVmax) and the mean SUV (SUVmean) of the thyroid gland and of the FTIU; every focal thyroid uptake deviating from physiological distribution and background was considered FTIU. Final diagnosis of FTIU was obtained by cytological or histological examination after surgery. RESULTS: The average SUVmax and SUVmean of thyroid gland in population were 3 and 1.8. Among 368 patients, FTIU was identified in nine cases (2.4%) and eight underwent further investigations to determine the nature. Two FTIU were classified as malignant (thyroid carcinoma), whereas five were benign (three nodular hyperplasia, one follicular adenoma, one Hurtle cell adenoma) and one indeterminate at cytological examination. In malignant lesions, average SUVmax was 9.6 and 4.5, respectively, while average SUVmean was 5.3 and 2.9, respectively. Average SUVmax and SUVmean of benign lesions were 4.9 and 3.2 and of the indeterminate lesion 5 and 3, respectively. CONCLUSIONS:18F-choline-PET/CT FTIU may be a relevant diagnostic reality, which requires further investigations and affects management, especially considering that, despite being mainly benign, also malignancy is possible.
Authors: M Salvatori; L Melis; P Castaldi; M L Maussier; V Rufini; G Perotti; D Rubello Journal: Biomed Pharmacother Date: 2007-06-13 Impact factor: 6.529
Authors: Orazio Schillaci; Ferdinando Calabria; Mario Tavolozza; Carmelo Cicciò; Marco Carlani; Cristiana R Caracciolo; Roberta Danieli; Antonio Orlacchio; Giovanni Simonetti Journal: Nucl Med Commun Date: 2010-01 Impact factor: 1.690
Authors: Adama Ouattara; Tiago Ribeiro de Oliveira; Serge Holz; Hannes Van den Bossche; David Strybol; Christophe Assenmacher; Wouter Everaerts; Gert De Meerleer; Steven Joniau Journal: Curr Urol Date: 2017-10-22
Authors: Jan Jamsek; Marko Hocevar; Damijan Bergant; Katja Zaletel; Sebastijan Rep; Luka Lezaic Journal: Ann Nucl Med Date: 2021-02-05 Impact factor: 2.668